Compounded versions are available at lower prices, though they are not FDA-approved branded products
Remember, weight loss with this treatment is generally gradual and steady, rather than rapid
No templates, no standard scriptsjust a curated strategy that respects your individuality
Appears to enhance weightloss and glucose effects when combined with GLP1, based on dualagonist data (such as tirzepatide). Glucagon receptor activation Increases energy expenditure and promotes fat oxidation when balanced properly with GLP1 and GIP. May help reduce liver fat and visceral (deep abdominal) fat, which are strongly linked to cardiometabolic risk. By combining these three pathways, retatrutide aims to reduce appetite, improve metabolic control, and increase calorie burning more strongly than current single or dualagonist drugs
All patients were 45 years or older, with an initial BMI of 27 kg/m 2 or greater and established CV disease (prior myocardial infarction, prior stroke, or peripheral arterial disease)